BH 30643
Alternative Names: BH-30643Latest Information Update: 16 Apr 2025
At a glance
- Originator BlossomHill Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Non-small cell lung cancer
Most Recent Events
- 04 Apr 2025 Pharmacodynamics data from a preclinical studies in Non-small cell lung cancer released by BlossomHill Therapeutics
- 09 Jan 2025 Phase-I/II clinical trials in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Japan (PO) (NCT06706076)
- 02 Dec 2024 Phase-I/II clinical trials in Non-small cell lung cancer (Late-stage disease, Second-line therapy or greater, Metastatic disease) in USA (PO) (NCT06706076)